Senti Biosciences (NASDAQ:SNTI) Shares to Reverse Split on Thursday, July 18th

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) are going to reverse split on the morning of Thursday, July 18th. The 1-10 reverse split was announced on Thursday, July 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, July 18th.

Senti Biosciences Stock Performance

Shares of SNTI stock remained flat at $0.31 during trading hours on Tuesday. The stock had a trading volume of 689,989 shares, compared to its average volume of 3,465,145. Senti Biosciences has a 1 year low of $0.21 and a 1 year high of $1.09. The business has a 50 day simple moving average of $0.32 and a 200-day simple moving average of $0.38.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.26) earnings per share (EPS) for the quarter. As a group, research analysts predict that Senti Biosciences will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Senti Biosciences

A hedge fund recently raised its stake in Senti Biosciences stock. ARK Investment Management LLC raised its position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,969,860 shares of the company’s stock after acquiring an additional 143,785 shares during the period. ARK Investment Management LLC owned approximately 4.42% of Senti Biosciences worth $1,300,000 as of its most recent filing with the Securities & Exchange Commission. 25.73% of the stock is currently owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.